[New Year's Address] Celltrion Group Chairman Seo Jungjin: "AI Is Transforming the Industrial Landscape... Strategic Decisions Needed"

Introduction of AI Platform
Maximizing Operational Efficiency Across All Business Areas

Seo Jungjin, Chairman of Celltrion Group, stated in his New Year’s address on the 2nd, “The three-year period from 2026 to 2028 will be a time for Celltrion to lay the foundation for innovation in preparation for a quantum leap,” adding, “With artificial intelligence fundamentally transforming the industrial landscape, now is the time to make strategic decisions to prepare for the future.”

To this end, Celltrion plans to introduce an AI platform to maximize work efficiency across all business areas. The company also intends to actively utilize AI adoption to expand its business not only in pharmaceuticals but also into the digital healthcare sector. In addition, a dedicated organization for new investments to drive future growth and change will be established within the company.

Chairman Seo, marking 2026 as the Year of the Fire Horse (Byeong-o Year), referenced the “Jeokto-ma,” the legendary red horse, and explained that he would take a proactive approach to on-site management. He said, “Just like the Jeokto-ma that Cao Cao gifted to Guan Yu, this year I will actively visit every corner of the field together with all executives and staff,” adding, “January and February will be the time to draw the map for where we will run, and starting in March, all employees will sprint forward together like the Jeokto-ma.”

He also presented detailed plans for each Celltrion Group company in 2026. First, Celltrion will expand its portfolio to around 40 products within the next decade to strengthen its foundation for stable profit generation. In the new drug sector, the company plans to further increase the number of clinical trials and expand its new drug pipeline to about 20 products. Additionally, with any further expansion of domestic and overseas facilities, Celltrion will increase AI-based efficiency, and through investments to enhance the efficiency of existing facilities, the company aims to further expand its production capacity.

With the company expected to achieve record-high results in 2025 since its founding, stable growth is anticipated to continue this year as well. According to Celltrion’s released fourth-quarter earnings forecast, last year’s annual sales reached 4.1163 trillion won, up 15.7% from the previous year. Operating profit is also projected to have increased by 136.9% to 1.1655 trillion won.

In addition, Celltrion Pharm will increase investment in the research and development of chemical pharmaceuticals to accelerate R&D speed, and plans to strengthen work capabilities through production automation and efficiency improvements incorporating IT. Celltrion Skincure will pursue a high value-added industry targeting the customized beauty market through collaboration with medical professionals. Celltrion Entertainment aims to enhance its content competitiveness by producing hybrid dramas utilizing AI and IT infrastructure.

Chairman Seo emphasized, “Celltrion will have a more dynamic year than any other company,” adding, “By keeping pace with the new changes brought by AI, we will create future achievements through timely strategic decisions and the operation of new business plans.”